Loss of PARP-1 activity not only decreases pro-tumor inflammation, but also inhibits two related hallmarks of cancer through anti-inflammatory mechanisms: proliferative signaling (32) and metastasis (33, 34) (Figure 1). Here, PARP1 is linked to cancer.